DE60032029D1 - Antithrombose agenzien - Google Patents

Antithrombose agenzien

Info

Publication number
DE60032029D1
DE60032029D1 DE60032029T DE60032029T DE60032029D1 DE 60032029 D1 DE60032029 D1 DE 60032029D1 DE 60032029 T DE60032029 T DE 60032029T DE 60032029 T DE60032029 T DE 60032029T DE 60032029 D1 DE60032029 D1 DE 60032029D1
Authority
DE
Germany
Prior art keywords
antithrombose
agencies
fixabs
suk
streptokinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032029T
Other languages
English (en)
Other versions
DE60032029T2 (de
Inventor
C Barone
N Blackburn
Z Feuerstein
R Toomey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE60032029D1 publication Critical patent/DE60032029D1/de
Application granted granted Critical
Publication of DE60032029T2 publication Critical patent/DE60032029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60032029T 2000-05-15 2000-10-05 Antithrombose agenzien Expired - Fee Related DE60032029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
US571434 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (2)

Publication Number Publication Date
DE60032029D1 true DE60032029D1 (de) 2007-01-04
DE60032029T2 DE60032029T2 (de) 2007-05-31

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032029T Expired - Fee Related DE60032029T2 (de) 2000-05-15 2000-10-05 Antithrombose agenzien

Country Status (20)

Country Link
US (1) US20050037006A1 (de)
EP (2) EP1825864A3 (de)
JP (1) JP2004516236A (de)
KR (2) KR20030034071A (de)
CN (2) CN101134107A (de)
AT (1) ATE345816T1 (de)
AU (2) AU2000278584B2 (de)
BR (1) BR0015872A (de)
CA (1) CA2411369A1 (de)
CZ (1) CZ20023778A3 (de)
DE (1) DE60032029T2 (de)
ES (1) ES2277597T3 (de)
HU (1) HU225874B1 (de)
IL (1) IL152831A0 (de)
MX (1) MXPA02011385A (de)
NO (1) NO20025463L (de)
NZ (1) NZ522632A (de)
PL (1) PL360060A1 (de)
WO (1) WO2001087339A1 (de)
ZA (1) ZA200209265B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2003079987A2 (en) 2002-03-20 2003-10-02 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
US10583094B2 (en) * 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
EP3103451A1 (de) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targeting des ncca-atp-kanals für organschutz nach einer ischämischen episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
JP7261739B2 (ja) 2017-04-27 2023-04-20 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE69901569T2 (de) * 1998-08-28 2002-12-19 Genentech Inc Humane antikörper gegen faktor ix/ixa

Also Published As

Publication number Publication date
NZ522632A (en) 2005-05-27
PL360060A1 (en) 2004-09-06
MXPA02011385A (es) 2004-01-26
CZ20023778A3 (cs) 2003-08-13
KR20070116192A (ko) 2007-12-06
BR0015872A (pt) 2004-08-03
HUP0301804A3 (en) 2005-12-28
AU7858400A (en) 2001-11-26
CN101134107A (zh) 2008-03-05
EP1825864A3 (de) 2007-09-12
KR20030034071A (ko) 2003-05-01
NO20025463D0 (no) 2002-11-14
HUP0301804A2 (hu) 2003-08-28
ES2277597T3 (es) 2007-07-16
EP1282444A1 (de) 2003-02-12
US20050037006A1 (en) 2005-02-17
EP1825864A2 (de) 2007-08-29
ATE345816T1 (de) 2006-12-15
HU225874B1 (en) 2007-11-28
AU2000278584B2 (en) 2006-11-16
WO2001087339A1 (en) 2001-11-22
EP1282444B1 (de) 2006-11-22
ZA200209265B (en) 2003-10-22
JP2004516236A (ja) 2004-06-03
NO20025463L (no) 2003-01-09
IL152831A0 (en) 2003-06-24
CN100339132C (zh) 2007-09-26
CN1501812A (zh) 2004-06-02
EP1282444A4 (de) 2004-06-30
CA2411369A1 (en) 2001-11-22
DE60032029T2 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
DK1232252T3 (da) Reversibel inaktiveret sur plasmin
DE60032029D1 (de) Antithrombose agenzien
ATE307111T1 (de) Serinprotease-inhibitoren
DE60134126D1 (de) 17-alpha-substituierte-11-beta-substituierte-4-aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
NO941561L (no) Bifunksjonelle urokinasevarianter med forbedrede fibrinolytiske egenskaper og trombinhemmende virkning
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
ATE103332T1 (de) Modifizierter gewebeplasminogenaktivator.
HN1999000116A (es) Isoquinolinas
EA200600573A1 (ru) Активаторы плазминогена, имеющие сниженную способность связывать лизин
DE59001558D1 (de) Thrombolytisch wirkendes kombinationspraeparat.
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee